Effectiveness of a once weekly subcutaneous epoetin beta treatment in hemodialysis patients To assess the efficacy of sc epoetin beta once weekly treatment to maintain stability of hemoglobin (Hb) in hemodialysis patients previously receiving intravenous (iv) darbepoetin alfa once weekly

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB (MetMAb) IN COMBINATION WITH 5 FLUOROURACIL, FOLINIC ACID, AND OXALIPLATIN (mFOLFOX6) IN PATIENTS WITH METASTATIC HER2 NEGATIVE, MET-POSITIVE GASTROESOPHAGEAL CANCER STUDIO DI FASE III, MULTICENTRICO, IN DOPPIO CIECO, CONTROLLATO CON PLACEBO, PER VALUTARE L'EFFICACIA E LA SICUREZZA DI ONARTUZUMAB (MetMAb), IN ASSOCIAZIONE CON 5-FLUOROURACILE, ACIDO FOLINICO E OXALIPLATINO (mFOLFOX6) IN PAZIENTI AFFETTI DA CARCINOMA GASTROESOFAGEO METASTATICO HER2 NEGATIVO, MET POSITIVO • To evaluate the efficacy of onartuzumab + mFOLFOX6 compared with placebo + mFOLFOX6 as measured by overall survival (OS) in patients with previously untreated HER2–negative metastatic gastroesopha...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomised, multicentre, multinational Phase II study to evaluate pertuzumab in combination with trastuzumab given either concomitantly or sequentially with standard anthracycline based chemotherapy or concomitantly with a non-anthracycline based chemotherapy regimen, as neoadjuvant therapy for patients with locally advanced, inflammatory or early stage HER2-positive breast cancer To make a preliminary assessment of the tolerability of neoadjuvant treatment with one of the following treatment regimens: Arm A FEC->T with trastuzumab and pertuzumab given from the start of the che...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Ph II/III seamless, multi-center, randomized, double-blind, placebo-controlled study of the reduction in signs and symptoms and inhibition of structural damage during treatment with tocilizumab versus placebo in patients with ankylosing spondylitis who have failed non-steroidal anti-inflammatory drugs and are naïve to TNF antagonist therapy To assess the: • Efficacy of treatment with TCZ 4 mg/kg and 8 mg/kg versus placebo in AS patients who are naïve to treatment with TNF antagonist therapy with regard to the proportion of patients who a...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Long term study to evaluate the safety and benefit of subcutaneous RoActemra/Actemra in the treatment of Juvenile Idiopathic Arthritis patients To evaluate the long-term safety of subcutaneous (SC) administration of TCZ in patients with pcJIA and sJIA To describe the long-term efficacy of SC TCZ in patients with pcJIA and sJIA

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Open-label, multicenter, dose-escalation Phase I/II study to evaluate safety, pharmacokinetics and activity of RO5126766, a dual Raf and MEK inhibitor, administered orally as monotherapy in patients with advanced tumors Part I of the study (Dose Escalation): - To determine the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicities (DLT) of RO5126766 administered on an oral continuous daily schedule. Part II of...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer who Have Received Prior Trastuzumab and Taxane Based Therapy. Estudio para evaluar la eficacia y seguridad de trastuzumab emtansine en combinación con Atezolizumab o Atezolizumab con placebo en los participantes con HER2-positivo de cáncer de mama localmente avanzado o metastásico que han recibido antes Trastuzumab y terapia basada en taxano To evaluate the efficacy of the combination of trastuzumab emtansine plus atezolizumab compared with trastuzumab emtansine plus placebo as measured by progression free survival (PFS) using Response Ev...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

HOFFMANN LA ROCHE BO21000 : Essai de phase 1 randomisé évaluant la tolérance et l’efficacité d’un traitement associant du RO5072759 à une chimiothérapie de type CHOP (cyclophosphamide, doxorubicine, vincristine, prednisone) ou de type FC (fludarabine, cyclophosphamide), chez des patients ayant un lymphome folliculaire à cellules B. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] A randomized, open label study to investigate the safety and effect on tumor response of RO5072759 given in combination with CHOP or FC chemotherapy in patients with CD20+ relapsed/refractory B-cell f...

• Pays France
• Organes Lymphomes non hodgkinien
• Spécialités Chimiothérapie, Thérapies Ciblées

Étude BP39365 : étude de phase 1b randomisée évaluant la sécurité d’emploi, la pharmacocinétique et l’efficacité du RO6874281 en association avec de l’atézolizumab avec ou sans bévacizumab chez des patients ayant un carcinome à cellules rénales non résécable avancé et/ou métastatique. Le carcinome à cellules rénales est le type le plus fréquent de cancer du rein. Il peut prendre naissance à partir de cellules de différentes parties du rein et avec le temps il peut s’étendre aux tis...

• Pays France
• Organes Rein, Appareil urinaire - autres
• Spécialités Immunothérapie - Vaccinothérapie

A Study of RO5072759 (GA101) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma Estudio de RO5072759 (GA101) más quimioterapia en comparación con MabThera (rituximab) más quimioterapia seguido de Mantenimiento con GA101 o MabThera en pacientes con linfoma no-Hodgkin indolente avanzado no tratado Progression-free survival in patients with follicular lymphoma, investigator-assessed according to the Revised Response Criteria for Malignant Lymphoma up to 7.5 years Supervivencia libre de pro...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune